We will be developing an EEG-based biomarker for the effects of ketamine infusion in patients with Depression. We will be analyzing the effects of ketamine infusion on Depression symptoms and EEG signals.
Who can participate
Age range18 Years ā 59 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Physically healthy patients who meet DMS-5 criteria for a major depressive episode (MDE) in the context of MDD and who score at least 22 on the Montgomery-Ć sberg Depression Rating Scale (MADRS)
* If taking antidepressants, dose is stable for at least 6 weeks.
Exclusion Criteria:
* Lifetime history of bipolar disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder, including MDD with psychotic features
* A first-degree relative with bipolar disorder, schizoaffective disorder, or schizophrenia, with the potential participant younger than 33 years (i.e., still at age of risk for a psychotic disorder)
* Receipt of electroconvulsive therapy within 3 months of enrolling in the study
* History of IV drug use
* Nonresponse or intolerance to ketamine administered either clinically or as part of a prior research study
* Pregnancy, planning to conceive, or sexually active but not using adequate birth control.
* Actively suicidal (CSSRSā„3)
* No antipsychotics or medications (e.g. benzodiazepines, anti-epileptics) that are likely to interact with GABA or glutamate,